MX2023013351A - Compuestos heterociclicos sustituidos. - Google Patents
Compuestos heterociclicos sustituidos.Info
- Publication number
- MX2023013351A MX2023013351A MX2023013351A MX2023013351A MX2023013351A MX 2023013351 A MX2023013351 A MX 2023013351A MX 2023013351 A MX2023013351 A MX 2023013351A MX 2023013351 A MX2023013351 A MX 2023013351A MX 2023013351 A MX2023013351 A MX 2023013351A
- Authority
- MX
- Mexico
- Prior art keywords
- substituted heterocyclic
- heterocyclic compounds
- compounds
- useful
- tyk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188498P | 2021-05-14 | 2021-05-14 | |
| US202263318508P | 2022-03-10 | 2022-03-10 | |
| PCT/US2022/029117 WO2022241174A1 (en) | 2021-05-14 | 2022-05-13 | Substituted heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013351A true MX2023013351A (es) | 2023-11-27 |
Family
ID=81927791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013351A MX2023013351A (es) | 2021-05-14 | 2022-05-13 | Compuestos heterociclicos sustituidos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11884650B2 (https=) |
| EP (1) | EP4337648B1 (https=) |
| JP (1) | JP7818623B2 (https=) |
| KR (1) | KR20240008338A (https=) |
| AU (1) | AU2022272725A1 (https=) |
| BR (1) | BR112023023726A2 (https=) |
| CA (1) | CA3218579A1 (https=) |
| ES (1) | ES3059456T3 (https=) |
| IL (1) | IL308422A (https=) |
| MX (1) | MX2023013351A (https=) |
| TW (1) | TW202311248A (https=) |
| WO (1) | WO2022241174A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12492184B2 (en) | 2020-12-22 | 2025-12-09 | InventisBio Co., Ltd. | Heteroaryl compounds, preparation methods and uses thereof |
| CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| EP4294806A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| KR20240008337A (ko) * | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| JP2024518791A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
| CN118812511A (zh) * | 2023-04-21 | 2024-10-22 | 浙江文达医药科技有限公司 | 作为tyk2抑制剂的杂环化合物及合成和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102233252B1 (ko) * | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| JP7631193B2 (ja) * | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| AU2019373203B2 (en) * | 2018-10-30 | 2024-10-24 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
| AU2021254764A1 (en) * | 2020-04-14 | 2022-11-03 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| KR20240008337A (ko) * | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| PE20250262A1 (es) * | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| JP2024518791A (ja) * | 2021-05-14 | 2024-05-02 | ブリストル－マイヤーズ スクイブ カンパニー | 置換ヘテロ環化合物 |
-
2022
- 2022-05-13 US US17/743,615 patent/US11884650B2/en active Active
- 2022-05-13 MX MX2023013351A patent/MX2023013351A/es unknown
- 2022-05-13 ES ES22727681T patent/ES3059456T3/es active Active
- 2022-05-13 WO PCT/US2022/029117 patent/WO2022241174A1/en not_active Ceased
- 2022-05-13 EP EP22727681.3A patent/EP4337648B1/en active Active
- 2022-05-13 BR BR112023023726A patent/BR112023023726A2/pt not_active Application Discontinuation
- 2022-05-13 IL IL308422A patent/IL308422A/en unknown
- 2022-05-13 AU AU2022272725A patent/AU2022272725A1/en not_active Abandoned
- 2022-05-13 KR KR1020237042732A patent/KR20240008338A/ko active Pending
- 2022-05-13 JP JP2023570166A patent/JP7818623B2/ja active Active
- 2022-05-13 TW TW111118147A patent/TW202311248A/zh unknown
- 2022-05-13 CA CA3218579A patent/CA3218579A1/en active Pending
-
2023
- 2023-12-14 US US18/539,519 patent/US20240124421A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4337648B1 (en) | 2025-12-24 |
| AU2022272725A1 (en) | 2024-01-04 |
| IL308422A (en) | 2024-01-01 |
| EP4337648A1 (en) | 2024-03-20 |
| KR20240008338A (ko) | 2024-01-18 |
| JP2024518555A (ja) | 2024-05-01 |
| US11884650B2 (en) | 2024-01-30 |
| WO2022241174A1 (en) | 2022-11-17 |
| TW202311248A (zh) | 2023-03-16 |
| US20240124421A1 (en) | 2024-04-18 |
| US20220388987A1 (en) | 2022-12-08 |
| BR112023023726A2 (pt) | 2024-01-30 |
| ES3059456T3 (en) | 2026-03-20 |
| JP7818623B2 (ja) | 2026-02-20 |
| CA3218579A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023015226A2 (es) | Compuestos heterocíclicos sustituidos | |
| MX2023013351A (es) | Compuestos heterociclicos sustituidos. | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| MX2022012306A (es) | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| CY1125784T1 (el) | Υποκατεστημενες δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της prmt5 | |
| CL2020001547A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa. | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| MX2021009276A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2. | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| MX392673B (es) | Derivados de pirazol como inhibidores de malt1 | |
| MX2021001486A (es) | Inhibidores prmt5. | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| CY1125169T1 (el) | ΕΝΩΣΕΙΣ ΑΜΙΝΟΠΥΡΑΖΙΝΟ ΔΙΟΛΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΡΙ3Κ-γ | |
| JOP20200086B1 (ar) | مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما | |
| CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| EA202092962A1 (ru) | Производные пиразола в качестве ингибиторов malt1 | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| CU20160195A7 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CL2020002139A1 (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado. | |
| MX2023008761A (es) | Derivado de benzotriazol novedoso que posee actividad inhibitoria contra la ectonucleotido pirofosfatasa - fosfodiesterasa y uso del mismo. | |
| MX2022000103A (es) | Compuestos para el tratamiento de trastornos oculares. | |
| MX2020011020A (es) | Compuestos farmaceuticamente efectivos que inhiben selectivamente las isoformas de miosina 2. | |
| EA202190125A1 (ru) | ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl |